Predict your next investment

Corporation
HEALTHCARE | Biotechnology
bionanogenomics.com

See what CB Insights has to offer

Founded Year

2003

Stage

Loan | IPO

Total Raised

$119.63M

Market Cap

0.74B

Stock Price

2.55

About BioNano Genomics

BioNano Genomics offers genome mapping and analysis tools aimed at helping researchers see genome structure to fill in what's missing from sequencing-based data. The company works with institutions in life science, translational research, molecular diagnostics and personalized medicine.

BioNano Genomics Headquarter Location

9640 Towne Centre Drive Suite 100

San Diego, California, 92121,

United States

267-499-2014

Latest BioNano Genomics News

BioNano Genomics Stock (BNGO): Why The Price Went Up Today

Jan 13, 2022

The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 1.46% today. This is why it happened. The stock price of BioNano Genomics Inc (NASDAQ: BNGO) – a pioneer of optical genome mapping (OGM) solutions on the Saphyr system and provider of NxClinical – increased by 1.46% today. During intraday trading, the company shares had increased by over 9%. Investors had responded positively to Bionano Genomics, the leading software solutions for visualization, interpretation, and reporting of genomic data, reporting unaudited preliminary financial highlights for the fourth quarter ended December 31, 2021. The company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available. Q4 2021 Highlights Bionano is expecting fourth-quarter 2021 revenue to be the range of $5.8 million to $6.2 million, an estimated increase of 25% to 33% compared to $4.7 million in the third quarter of 2021 and an estimated increase of 45% to 55% compared to the fourth quarter of 2020. And the full year 2021 revenue is expected to be in the range of $17.5 million and $17.9 million, an increase of between 106% and 110% compared to 2020. Plus Bionano also reported a record net increase in the installed base of 23 Saphyr systems in the fourth quarter of 2021, bringing the year-end total to 164, representing a 69% increase over the 97 installed systems reported at the end of 2020 and exceeding our goal of 150 systems by the end of 2021. Achieved Full-Year 2021 Milestones, Exceeded Q4 2021 Goals Q421: Published interim results from our constitutional postnatal study Q421: Three Saphyr users validated laboratory-developed tests for their application of the OGM workflow Q421: Completed initial prototype of next-gen high throughput Saphyr Q421: Reached installed base of 164 systems to achieve a 69% increase over year-end 2020 and exceeded our stated goal of 150 systems Bionano has not completed the preparation of its financial statements for the fourth quarter or a full year of 2021. The revenue ranges presented for the fourth quarter of 2021 and for the year ended December 31, 2021, are preliminary and unaudited and are thus inherently uncertain and subject to change as the company completes the financial results for the fourth quarter of 2021. KEY QUOTES: “We ended the year with a lot of momentum across the business and have achieved or exceeded all of the milestones we set out at the beginning of 2021. The integration of BioDiscovery is going well and the results from our first interim readout from our postnatal clinical trial exceeded our expectations. Additionally, there is a lot of excitement around our 2022 Symposium, which began earlier this week.” — Erik Holmlin, PhD, President and Chief Executive Officer of Bionano “The growth in revenues we expect to report for the fourth quarter and full-year 2021 compared to the same periods in 2020 are what we’ve been working hard to achieve. When we combine that momentum with the nearly 70 percent increase in the size of the installed base, we feel we are laying the groundwork for a very exciting year in 2022.” — Chris Stewart, Chief Financial Officer of Bionano Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioNano Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioNano Genomics is included in 2 Expert Collections, including Omics.

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

12,248 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

BioNano Genomics Patents

BioNano Genomics has filed 35 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Genetics
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/4/2019

5/4/2021

Molecular biology, Genetics, DNA, Biotechnology, Genomics

Grant

Application Date

10/4/2019

Grant Date

5/4/2021

Title

Related Topics

Molecular biology, Genetics, DNA, Biotechnology, Genomics

Status

Grant

BioNano Genomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioNano Genomics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.